SinoMab (03681.HK) Publishes Preclinical Studies for SM17 in ERJ Open Research, Highlighting Strong Therapeutic Potential in CRSwNP and IPF Treatment

【For Immediate Release】 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 (Incorporated in Hong Kong with limited liability) (Stock code: 3681) SinoMab (03681.HK) Publishes Preclinical Studies for SM17 in ERJ Open Research, Highlighting Strong Therapeutic Potential in CRSwNP and IPF Treatment (20 February 2026 – Hong Kong) A Hong Kong -based biopharmaceutical company dedicated to the research, development of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (“SinoMab” or the “Company”, Stock Code: 3681.HK), is pleased to announce that the preclinical data for SM17, a first-in-class anti-IL-17RB antibody has been published in ERJ Open Research , which demonstrates that SM17 significantly ameliorates pathological features in chronic rhinosinusitis with nasal polyps (CR SwNP) and idiopathic pulmonary fibrosis (IPF) via dual suppression of Th2/Th17 pathways and anti-fibrotic activity, supporting its potential as a transformative therapy. SM17 functions by blocking the IL -25/IL-17RB signaling pathway. The research demonstrates that IL-25 is an upstream regulator that drives both Th2 and Th17 inflammatory pathways. SM17 exhibits a dual mechanism by suppressing Th2-mediated eosinophilic inflammation and Th17 differentiation, the latter occurring through the inhibition of IL -25-induced M2 macrophage polarization. Additionally, SM17 directly inhibits IL-25-driven fibroblast activation and epithelial-mesenchymal transition (EMT), showcasing anti-fibrotic properties. The stud y shows that in an ovalbumin/SEB -induced murine model, SM17 administration significantly restored olfactory function, reduced nasal polyp burden, and suppressed key pathological features, including eosinophil infiltration, goblet cell hyperplasia, and Th2 cytokine levels. Its efficacy showed a trend of improvement over dexamethasone. In a bleomycin-induced pulmonary fibrosis model, SM17 demonstrated comparable efficacy to the approved drug nintedanib (Nin) in reducing collagen deposition and Ashcroft score. Notably, SM17 uniquely attenuated Th17 cell infiltration in the lungs and showe d a trend of better suppression of α-SMA expression compared to both nintedanib and pirfenidone. Transcriptomic analysis (RNA-seq) suggested that SM17 modulates a broader range of fibrotic and immune-response genes than nintedanib. Dr. Shui On Leung, Chairman, Executive Director, and Chief Executive Officer of SinoMab , “we are very pleased to announce the publication of our preclinical studies on SM17 in ERJ Open Research, highlighting its potential to treat CRSwNP and IPF. These results position SM17 as a promising, potential first-in-class biologic that targets a central upstream alarmin (IL-25). By simultaneously addressing Th2 inflammation, Th17 differentiation, and fibrosis, SM17 may offer a multifaceted therapeutic strategy for CRSwNP and IPF, potentially filling unmet needs where current therapies targeting downstream effectors have limitations. Apart from CRSwNP and IPF, we continue to advance the clinical development of SM17 for atopic dermatitis as the Phase II clinical trial will soon be initiated. These milestones underscore our strategy to develop SM17 as pipeline-in-a-pill. We’re looking forward to sharing more clinical progress in near future.” For more information about this study: https://publications.ersnet.org/content/erjor/early/2026/01/22/2312054101067-2025 About SinoMab BioScience Limited SinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative diseases, and other debilitating dis eases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existin g therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of atopic dermatitis, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti -CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) an d Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simu ltaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited. Investor and Media Enquiries Contact Person: Bunny Lee / Wendy Huang / Trudy Huang Phone: (852) 5316 9995 Email: [email protected]

The release as fetched from its publisher. sinomab.com ↗